Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Lymphoma × loncastuximab tesirine × Clear all

Status

No longer available 1

Sponsor Class

Study Type

Interventional 7 Expanded_access 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1

Interventions

tipifarnib 1 loncastuximab tesirine 1 glucarpidase 1 fludarabine phosphate 1 Whole-Body Irradiation 1 Tacrolimus 1 Mycophenolic Acid 1 Cytarabine 1 Cord Blood Stem Cell Transplantation 1 Carboxypeptidases 1 Busulfan 1 Brentuximab Vedotin 1 Bone Marrow Transplantation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04705454 2021-05-12

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics S.A.

No longer available

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡